Biogen EBITDA 2010-2022 | BIIB

Biogen annual and quarterly EBITDA history from 2010 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Biogen EBITDA for the quarter ending March 31, 2022 was $0.754B, a 32.74% decline year-over-year.
  • Biogen EBITDA for the twelve months ending March 31, 2022 was $3.591B, a 18.36% decline year-over-year.
  • Biogen 2021 annual EBITDA was $3.958B, a 24.14% decline from 2020.
  • Biogen 2020 annual EBITDA was $5.217B, a 32.45% decline from 2019.
  • Biogen 2019 annual EBITDA was $7.723B, a 18.11% increase from 2018.
Biogen Annual EBITDA
(Millions of US $)
2021 $3,958
2020 $5,217
2019 $7,723
2018 $6,539
2017 $6,427
2016 $5,834
2015 $5,491
2014 $4,661
2013 $3,047
2012 $2,221
2011 $2,084
2010 $1,605
2009 $1,723
Biogen Quarterly EBITDA
(Millions of US $)
2022-03-31 $754
2021-12-31 $722
2021-09-30 $971
2021-06-30 $1,145
2021-03-31 $1,121
2020-12-31 $-31
2020-09-30 $1,220
2020-06-30 $2,087
2020-03-31 $1,940
2019-12-31 $1,891
2019-09-30 $2,136
2019-06-30 $2,073
2019-03-31 $1,624
2018-12-31 $1,407
2018-09-30 $2,044
2018-06-30 $1,385
2018-03-31 $1,704
2017-12-31 $1,675
2017-09-30 $1,831
2017-06-30 $1,384
2017-03-31 $1,537
2016-12-31 $1,065
2016-09-30 $1,606
2016-06-30 $1,636
2016-03-31 $1,528
2015-12-31 $1,324
2015-09-30 $1,524
2015-06-30 $1,378
2015-03-31 $1,266
2014-12-31 $1,317
2014-09-30 $1,328
2014-06-30 $1,153
2014-03-31 $862
2013-12-31 $816
2013-09-30 $832
2013-06-30 $791
2013-03-31 $608
2012-12-31 $542
2012-09-30 $629
2012-06-30 $596
2012-03-31 $453
2011-12-31 $498
2011-09-30 $576
2011-06-30 $501
2011-03-31 $509
2010-12-31 $451
2010-09-30 $284
2010-06-30 $483
2010-03-31 $386
2009-12-31 $477
2009-09-30 $470
2009-06-30 $350
2009-03-31 $427
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $29.662B $10.982B
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00